Sergio Fazio, MD, PhD
Eliot Brinton, MD, FAHA, FNLA
Michael Miller, MD
Margo Minissian, PhD, ACNP
John R. Nelson, MD, FACC, FNLA, FASNC
Dialogues from the Dais: Lipid Manage...
December 10, 2020
07:00 PM - 08:30 PM CST
Dominick Angiolilo, MD
Virtual Grand Rounds: Redefining the ...
October 20, 2020
12:00 PM - 01:00 PM EDT
07:00 PM - 08:00 PM EDT
George Bakris, MD
Matthew R. Weir, MD
Faiez Zannad, MD, PhD
Potassium Management Made Easy
Austin G. Stack, MBBCh, MD, MSc, FASN, FRCPI
Mikhail Kosiborod, MD
Management of Heart Failure: Time to Consider New Options?
Michel Farnier, MD, PhD
Børge G. Nordestgaard, MD, DMSc
Omega-3 Fatty Acids in Patients with ASCVD Risk: The Role of Icosapent Ethyl ...
Christopher P. Cannon, MD
Samuel Dagogo-Jack, MD, DSc
Is It Time to Change Your Treatment Strategy for Type 2 Diabetes Patients wit...
Javed Butler, MD, MPH, MBA
Mr. Jackson Moves to Town: Overcoming Challenges to Optimizing RAASi Therapy
Ewa A. Jankowska, MD, PhD, FESC
Stefan D. Anker, MD, PhD
Beyond Anemia: Understanding the Significance and Treatment of Iron Deficiency
Balancing RAASi Therapy and Potassium: Understanding How it Works
Mechanisms in Heart Failure: Why Iron Deficiency Matters
Robert J. Mentz, MD
Piotr Ponikowski, MD, PHD, FESC, FHFA
Don’t Be Fooled: It’s Not Just Anemia, It’s Iron Deficiency
Practical Considerations to Manage Residual ASCVD Risk
Ileana L. Piña, MD, MPH, FAHA, FACC
Patrick Rossignol, MD, PhD
Potassium Binders in Heart Failure: Who, When, and How
Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Examining Heart Failure Management: How Can We Do Better?
Prof. Stephen Nicholls
Prof. Kausik Ray
Examining LDL Cholesterol and Our Growing Therapy Options in Primary Prevention
